Dark

Check out our Level2View

EFTR
EFFECTOR THERAPUTCS INC
stock OTC

Inactive

Jul 29, 2026

0.000200USD-75.000%(-0.000600)181

Pre-market

0.00USD-100.000%(0.00)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 25, 2022

04:39PM EST eFFECTOR Therapeutics Files For Resale of Up To 8.13M Shares Benzinga

10:03AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 25, 2022 Benzinga

09:24AM EST Analyst Ratings For eFFECTOR Therapeutics Benzinga

09:23AM EST 10 Biggest Price Target Changes For Tuesday Benzinga

08:09AM EST Credit Suisse Maintains Outperform on eFFECTOR Therapeutics, Lowers Price Target to $16 Benzinga

07:57AM EST Stifel Downgrades eFFECTOR Therapeutics to Hold, Lowers Price Target to $6.2 Benzinga

06:38AM EST JMP Securities Maintains Market Outperform on eFFECTOR Therapeutics, Lowers Price Target to $8 Benzinga

Jan 24, 2022

04:11PM EST eFFECTOR Therapeutics Provides Pipeline And Business Updates And Establishes Investment Agreement With Lincoln Park Capital For $50M Benzinga

04:00PM EST Tomivosertib development strategy updated, including addition of a new cohort in Phase 2b KICKSTART trial in non-small cell lung cancer (NSCLC) evaluating frontline maintenance in PD-L1 1% patient population, representing additional $5 billion U.S. market opportunity GlobeNewswire Inc

Nov 24, 2021

08:04AM EST eFFECTOR Therapeutics Highlights Publication Of Zotatifin Preclinical Data In Frontiers In Oncology Benzinga

08:00AM EST eFFECTOR Therapeutics Announces Publication of Zotatifin GlobeNewswire Inc

Nov 22, 2021

08:00AM EST eFFECTOR Therapeutics to Participate in The JMP Securities GlobeNewswire Inc

Nov 9, 2021

12:02PM EST Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2021 Benzinga

11:24AM EST Stifel Upgrades eFFECTOR Therapeutics to Buy, Announces $20 Price Target Benzinga

11:07AM EST Watching EFFECTOR Therapeutics; Hearing Stifel Upgrades To Buy, Sets $20 Price Target Benzinga

Nov 8, 2021

07:07AM EST eFFECTOR Therapeutics Q3 EPS $0.42 Up From $(5.29) YoY, Sales $427.00K Down From $574.00K YoY Benzinga

07:00AM EST Continuing to enroll patients in Phase 2b KICKSTART study of tomivosertib in combination with pembrolizumab, a U.S. Food and Drug Administration (FDA) approved PD-1 inhibitor GlobeNewswire Inc

Nov 1, 2021

04:05PM EDT eFFECTOR Appoints Barbara Klencke, M.D., to Board of Directors GlobeNewswire Inc

Oct 26, 2021

08:00AM EDT eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that management will participate in and host 1x1 meetings at the following upcoming investor conferences: GlobeNewswire Inc

Oct 12, 2021

10:48AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2021 Benzinga

06:15AM EDT Credit Suisse Initiates Coverage On eFFECTOR Therapeutics with Outperform Rating, Announces Price Target of $20 Benzinga

Oct 8, 2021

06:51AM EDT The following are some of the stocks making big moves in Friday's pre-market trading (as of 6.30 A.M. EDT). RTTNews

Oct 7, 2021

04:31PM EDT Baylor College Of Medicine Presents eFFECTOR Therapeutics-Backed Preclinical Data Supporting Development Of Zotatifin In Triple-Negative Breast Cancer At 2021 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics Benzinga

04:30PM EDT Demonstrated statistically significant anti-tumor activity and inhibited proliferative and stem-cell signaling pathways GlobeNewswire Inc

Oct 4, 2021

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 4, 2021 Benzinga

06:07AM EDT Mizuho Initiates Coverage On eFFECTOR Therapeutics with Buy Rating, Announces Price Target of $20 Benzinga

Sep 30, 2021

04:33PM EDT Baylor College Of Medicine To Present eFFECTOR Therapeutics-Supported Research At AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics Benzinga

04:32PM EDT Baylor College of Medicine to Present eFFECTOR GlobeNewswire Inc

Sep 21, 2021

10:33AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2021 Benzinga

06:59AM EDT JMP Securities Initiates Coverage On eFFECTOR Therapeutics with Market Outperform Rating, Announces Price Target of $33 Benzinga

Sep 20, 2021

10:04AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 20, 2021 Benzinga

08:23AM EDT Stifel Initiates Coverage On eFFECTOR Therapeutics with Hold Rating, Announces Price Target of $20 Benzinga

Sep 16, 2021

08:00AM EDT eFFECTOR Therapeutics to Participate in 2021 Cantor Virtual GlobeNewswire Inc

Sep 13, 2021

02:54PM EDT What's Going On With eFFECTOR Therapeutics Stock Today? Benzinga

10:38AM EDT Shares of eFFECTOR Therapeutics, Inc. (EFTR) gained nearly 10% on Monday morning despite no stock related news to drive the shares. RTTNews

10:18AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2021 Benzinga

06:16AM EDT Cantor Fitzgerald Initiates Coverage On eFFECTOR Therapeutics with Overweight Rating, Announces Price Target of $50 Benzinga

Sep 9, 2021

05:35AM EDT The following are some of the stocks making big moves in Thursday's pre-market trading (as of 5.25 A.M. EDT). RTTNews

Sep 8, 2021

05:52AM EDT The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 5.25 A.M. EDT). RTTNews

Aug 27, 2021

10:10AM EDT Mid-Morning Market Update: Markets Open Higher; Big Lots Reports Downbeat Profit Benzinga

Share